Drug
Ptc299
Ptc299: highest development phase Phase 2/3, developed by PTC Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- PTC Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| PTC299 NCT04439071 | Phase 2/3 | Pneumonia |
| PTC299 NCT03761069 | Phase 1 | Leukemia, Myeloid, Acute |
Latest
No recent events.
Follow Ptc299 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.